查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1782997

全球胜肽和寡核苷酸CDMO市场

Peptide and Oligonucleotide CDMO
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 370 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球胜肽和寡核苷酸 CDMO 市场规模将达到 57 亿美元

全球胜肽和寡核苷酸CDMO市场规模预计在2024年为28亿美元，预计到2030年将达到57亿美元，在2024-2030年的分析期内，复合年增长率为12.8%。肽类是本报告分析的细分市场之一，预计其复合年增长率为14.1%，到分析期结束时规模将达到42亿美元。寡核苷酸细分市场在分析期间内的复合年增长率估计为9.4%。

美国市场规模估计为 7.523 亿美元，中国市场预计复合年增长率为 17.3%

美国胜肽和寡核苷酸CDMO市场规模预计在2024年达到7.523亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到12亿美元，在2024-2030年的分析期内，复合年增长率将达到17.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为9.2%和11.4%。在欧洲，预计德国市场的复合年增长率将达到10.1%。

全球胜肽和寡核苷酸 CDMO 市场 - 主要趋势和驱动因素摘要

什么是胜肽和寡核苷酸 CDMO？

胜肽和寡核苷酸合约开发与受託製造厂商(CDMO) 专门从事胜肽和寡核苷酸的开发和生产。这些生物製药对于开发多种疾病的治疗方法至关重要，包括癌症、自体免疫疾病、遗传性疾病和病毒感染疾病。胜肽和寡核苷酸 CDMO 的作用是提供与这些复杂分子的研究、开发和大规模生产相关的服务。这些服务通常包括药物发现、製程开发、製造和商业化支持，确保产品符合製药业的严格监管要求。

与传统小分子药物相比，肽类药物因其特异性更高、毒性更低而日益受到青睐。寡核苷酸（包括基于RNA的疗法和反义寡核苷酸等产品）因其靶向和调控基因表现的能力而变得越来越重要。专注于胜肽类和寡核苷酸的CDMO（合约开发生产组织）帮助製药公司克服生产这些高度专业化分子的挑战，包括克服与可扩展性、纯度、产量优化以及确保合规性相关的挑战。随着胜肽类和寡核苷酸药物市场的持续扩张，预计该领域对CDMO服务的需求将大幅成长。

胜肽和寡核苷酸 CDMO 市场为何不断扩大？

胜肽和寡核苷酸CDMO市场正在扩张，这得益于几个关键因素，包括生技药品和个人化医疗的兴起、RNA疗法的进步以及慢性病盛行率的上升。其中一个最显着的驱动因素是生物製药（尤其是胜肽和生物製药）的日益普及，它们特异性高、副作用少，能够治疗先前难以控制的疾病，例如罕见遗传疾病、某些癌症和病毒感染疾病。

RNA治疗方法的进步也是推动胜肽和寡核苷酸 CDMO 市场成长的重要因素。 mRNA 疫苗在对抗 COVID-19 疫情的成功，凸显了 RNA 技术在医疗保健领域的潜力。因此，对寡核苷酸製造服务的需求正在快速增长，尤其是对 mRNA 疫苗、基因编辑工具和RNA干扰疗法等产品的需求。製药和生物技术公司越来越多地寻求在此类复杂分子製造和开发方面拥有专业知识的 CDMO 合作伙伴。随着 RNA 疗法研究的深入，对包括小干扰 RNA (siRNA)、传讯RNA(mRNA) 和反义寡核苷酸 (ASO) 在内的寡核苷酸的需求预计将持续上升。

此外，癌症、糖尿病和心血管疾病等慢性疾病的日益流行，也推动了对新型治疗方法的需求，包括胜肽和寡核苷酸。随着世界人口老化，对在分子层面上针对这些疾病根本病因的创新药物的需求日益增长。这导致越来越多的基于胜肽和寡核苷酸的候选药物进入临床和商业化阶段，进一步增加了对CDMO提供的专业生产和开发服务的需求。

影响胜肽和寡核苷酸 CDMO 未来的主要趋势是什么？

胜肽和寡核苷酸CDMO市场的未来正受到多种变革趋势的影响，包括製造技术的进步、品质和法规遵循日益重要，以及对扩充性和灵活性的日益关注。其中一个关键趋势是胜肽和寡核苷酸合成技术的进步，这使得製造流程更快、更有效率、更具成本效益。固相胜肽合成(SPPS)、连续流化学和自动化高通量系统等创新技术正在提高大规模生产高品质胜肽和寡核苷酸的能力，这对于满足日益增长的全球需求至关重要。

此外，包括胜肽和寡核苷酸在内的生技药品的法规环境日益严格，这进一步要求CDMO加强品管措施，确保符合全球法规。这包括满足美国FDA和欧洲药品管理局(EMA)等监管机构制定的要求，这些机构对生技药品的开发、生产和分销制定了严格的指导方针。随着生技药品日益复杂，CDMO必须始终领先于不断发展的监管标准，并采用最佳实践，以确保其生产流程完全合规，并生产出纯度和功效达到最高水平的治疗药物。

另一个关键趋势是对灵活且可扩展的生产解决方案的需求日益增长。随着基于胜肽和寡核苷酸的疗法在临床研发管线中不断推进，药物开发商需要能够提供灵活生产能力的CDMO，并能够随着药物开发的进展而扩展。这种灵活性对于製药公司在保持成本效益、品质和法规合规性的同时高效扩大生产规模至关重要。随着个人化医疗和标靶治疗的日益普及，CDMO也需要具备适应能力，以提供能够满足每种候选药物独特需求的客製化解决方案。

推动胜肽和寡核苷酸 CDMO 市场成长的因素有哪些？

胜肽和寡核苷酸CDMO市场的成长受到多种因素的推动，包括对生技药品需求的不断增长、RNA治疗方法的进步以及对基因标靶疗法研究的活性化。随着製药业持续向生物製药转型，胜肽和寡核苷酸因其能够更精准地靶向特定生物过程且副作用更少而备受关注。这导致专注于这些治疗方法的研发活动激增，从而导致对能够提供这些分子製造和规模化专业知识的专业CDMO服务的需求增加。

RNA治疗方法（尤其是 mRNA 疫苗和基因疗法）的快速发展和核准，进一步加速了 CDMO 产业的成长。随着新冠疫情 mRNA 疫苗的成功研发，人们对扩大 RNA 技术的应用范围以治疗更多疾病的兴趣日益浓厚。这导致对拥有先进寡核苷酸合成和 RNA 生产能力的 CDMO 的需求日益增长。随着 RNA 疗法产品线的不断拓展，专注于寡核苷酸生产的 CDMO 具备优势，能够支持製药公司扩大生产规模，以用于临床试验和商业性上市。

此外，个人化医疗日益受到重视，这推动了对更专业、小规模、高品质胜肽和寡核苷酸生产服务的需求。随着越来越多的药物被开发用于针对特定基因标记或疾病亚型，能够适应小批量客製化并保持高品质的精准生产变得越来越重要。为了支持这些创新，对能够提供灵活、可扩展且高品质生产能力的CDMO的需求日益增长。此外，慢性病的日益普及以及基因编辑疗法的转变，也促进了胜肽和寡核苷酸CDMO市场的扩张。

部分

产品类型（胜肽、寡核苷酸）；服务类型（契约製造服务、合约开发服务）；最终用户（製药公司、生物製药公司、其他最终用户）

受访公司范例

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Almac Group
  • Aurigene Pharmaceutical Services Ltd.
  • Bachem Holding AG
  • BioSynthesis Inc.
  • Catalent, Inc.
  • CordenPharma International
  • EUROAPI
  • GenScript Biotech Corporation
  • Kaneka Eurogentec SA
  • Lonza Group AG
  • Merck KGaA
  • Piramal Pharma Solutions
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Senn Chemicals AG
  • STA Pharmaceutical Co., Ltd.（WuXi STA）
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP32516

Global Peptide and Oligonucleotide CDMO Market to Reach US$5.7 Billion by 2030

The global market for Peptide and Oligonucleotide CDMO estimated at US$2.8 Billion in the year 2024, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2024-2030. Peptides, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Oligonucleotides segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$752.3 Million While China is Forecast to Grow at 17.3% CAGR

The Peptide and Oligonucleotide CDMO market in the U.S. is estimated at US$752.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Peptide and Oligonucleotide CDMO Market - Key Trends & Drivers Summarized

What Is a Peptide and Oligonucleotide CDMO and How Does It Work?

A Peptide and Oligonucleotide Contract Development and Manufacturing Organization (CDMO) specializes in the development and manufacturing of peptides and oligonucleotides, which are short chains of amino acids and nucleotides, respectively. These biopharmaceutical products are crucial in the development of therapeutics for a range of diseases, including cancer, autoimmune disorders, genetic diseases, and viral infections. The role of a peptide and oligonucleotide CDMO is to provide services related to the research, development, and large-scale production of these complex molecules. These services typically include drug discovery, process development, manufacturing, and commercialization support, ensuring that the products meet the stringent regulatory requirements of the pharmaceutical industry.

Peptide drugs are gaining significant traction due to their specificity and lower toxicity compared to traditional small-molecule drugs. Oligonucleotides, which include products like RNA-based therapeutics and antisense oligonucleotides, are becoming increasingly important for their ability to target and modulate gene expression. CDMOs focused on peptides and oligonucleotides help pharmaceutical companies navigate the challenges of producing these highly specialized molecules. This includes overcoming challenges related to scalability, purity, yield optimization, and ensuring regulatory compliance. As the market for peptide and oligonucleotide-based drugs continues to expand, the demand for CDMO services in this space is poised to increase substantially.

Why Is the Peptide and Oligonucleotide CDMO Market Expanding?

The peptide and oligonucleotide CDMO market is growing due to several key factors, including the rise of biologics and personalized medicine, advances in RNA therapies, and the increasing prevalence of chronic diseases. One of the most prominent drivers is the growing shift toward biologic drugs, particularly peptides and oligonucleotides, which are considered more targeted and precise compared to traditional small-molecule drugs. These biologics offer higher specificity, fewer side effects, and can be used to treat diseases that were previously challenging to manage, such as rare genetic disorders, certain cancers, and viral infections.

The advancement of RNA-based therapies is another major factor contributing to the growth of the peptide and oligonucleotide CDMO market. The success of mRNA vaccines in combating the COVID-19 pandemic has highlighted the potential of RNA technologies in medicine. As a result, the demand for oligonucleotide manufacturing services is rapidly increasing, particularly for products like mRNA vaccines, gene-editing tools, and RNA interference therapies. Pharmaceutical companies and biotech firms are increasingly seeking CDMO partners with expertise in the production and development of these complex molecules. The demand for oligonucleotides, including small interfering RNA (siRNA), messenger RNA (mRNA), and antisense oligonucleotides (ASOs), is expected to continue its upward trajectory as research into RNA therapeutics expands.

In addition, the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is driving the need for novel therapeutic approaches, including those involving peptides and oligonucleotides. As the global population ages, there is an escalating demand for innovative drugs that target the underlying causes of these diseases at a molecular level. This has led to a growing number of peptide and oligonucleotide-based drug candidates entering the clinical and commercial stages, further increasing the demand for specialized manufacturing and development services offered by CDMOs.

What Key Trends Are Shaping the Future of Peptide and Oligonucleotide CDMOs?

The future of the peptide and oligonucleotide CDMO market is being shaped by several transformative trends, including advances in manufacturing technologies, the increasing importance of quality and regulatory compliance, and the growing focus on scalability and flexibility. One key trend is the advancement of peptide and oligonucleotide synthesis technologies, which are enabling faster, more efficient, and cost-effective manufacturing processes. Innovations in solid-phase peptide synthesis (SPPS), continuous-flow chemistry, and automated high-throughput systems are improving the ability to produce high-quality peptides and oligonucleotides at scale, which is critical for meeting the increasing global demand.

Additionally, the regulatory environment for biologics, including peptides and oligonucleotides, is becoming more stringent, driving the need for CDMOs to enhance their quality control measures and ensure compliance with global regulations. This includes meeting the requirements set by regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA), which have strict guidelines for the development, manufacturing, and distribution of biologics. As the complexity of biologics increases, CDMOs will need to stay ahead of evolving regulatory standards and adopt best practices to ensure that their manufacturing processes are fully compliant and capable of producing therapeutics with the highest levels of purity and efficacy.

Another important trend is the growing demand for flexible and scalable manufacturing solutions. As peptide and oligonucleotide-based therapeutics move through the clinical pipeline, drug developers require CDMOs that can provide flexible manufacturing capabilities that scale with the progression of the drug’s development. This flexibility is essential as it allows pharmaceutical companies to efficiently scale up production while maintaining cost-effectiveness, quality, and regulatory compliance. As personalized medicine and targeted therapies become more common, CDMOs will also need to be adaptable in offering customized solutions that can cater to the unique needs of individual drug candidates.

What Are the Key Drivers of Growth in the Peptide and Oligonucleotide CDMO Market?

The growth in the peptide and oligonucleotide CDMO market is driven by several factors, including increasing demand for biologics, advancements in RNA-based therapies, and growing research into gene-targeted treatments. As the pharmaceutical industry continues to shift toward biologic drugs, peptides and oligonucleotides have gained significant attention due to their ability to target specific biological processes with higher precision and fewer side effects. This has led to a surge in research and development activities focused on these therapeutic modalities, thereby increasing the demand for specialized CDMO services that can provide expertise in the manufacturing and scale-up of these molecules.

The rapid development and approval of RNA-based therapies, especially mRNA vaccines and gene therapies, have further fueled growth in the CDMO sector. Following the success of mRNA vaccines for COVID-19, there has been a heightened interest in expanding the application of RNA technologies to treat a broader range of diseases. This has driven the need for CDMOs with advanced capabilities in oligonucleotide synthesis and RNA production. As the pipeline for RNA-based therapeutics grows, CDMOs that specialize in oligonucleotide manufacturing are well-positioned to support pharmaceutical companies as they scale up production for clinical trials and commercial launch.

Additionally, the increasing focus on personalized medicine is driving the need for more specialized, small-scale, high-quality peptide and oligonucleotide manufacturing services. As more drugs are developed to target specific genetic markers or disease subtypes, there is a greater emphasis on precision manufacturing that can accommodate smaller, customized batches while maintaining high levels of quality. CDMOs that offer flexible, scalable, and high-quality production capabilities are increasingly in demand to support these innovations. Moreover, the growing prevalence of chronic diseases and the shift toward gene-editing therapies are contributing to the expansion of the peptide and oligonucleotide CDMO market, as these technologies offer new avenues for treating previously untreatable conditions.

SCOPE OF STUDY:

The report analyzes the Peptide and Oligonucleotide CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Peptides, Oligonucleotides); Service Type (Contract Manufacturing Service, Contract Development Service); End-Use (Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Almac Group
  • Aurigene Pharmaceutical Services Ltd.
  • Bachem Holding AG
  • BioSynthesis Inc.
  • Catalent, Inc.
  • CordenPharma International
  • EUROAPI
  • GenScript Biotech Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • Merck KGaA
  • Piramal Pharma Solutions
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Senn Chemicals AG
  • STA Pharmaceutical Co., Ltd. (WuXi STA)
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Peptide and Oligonucleotide CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted Therapies Propels Growth of Peptide and Oligonucleotide CDMO Services
    • Surging Investments in mRNA and RNAi Technologies Expands Addressable Market Opportunity for Oligonucleotide CDMOs
    • Advancements in Solid-Phase Peptide Synthesis (SPPS) Strengthen Business Case for Outsourcing Complex Peptides
    • Biopharma Industry's Shift Toward Outsourcing Accelerates Demand for End-to-End CDMO Partnerships
    • Expanding Applications of Peptides in Metabolic and Oncology Therapies Drives Market Penetration
    • Regulatory Encouragement for Orphan and Rare Disease Drugs Throws the Spotlight on Oligonucleotide-Based Therapies
    • Growing Pipeline of Nucleic Acid Therapeutics Spurs Long-Term CDMO Opportunities
    • Increasing Complexity of Molecule Design Generates Demand for Specialized CDMO Capabilities
    • Personalized Medicine Trends Drive Adoption of Custom Peptide and Oligo Synthesis Services
    • Emergence of Cell and Gene Therapies Expands Synergistic Opportunities for Nucleic Acid CDMOs
    • Emergence of Next-Generation Sequencing (NGS) Tools Strengthens Market for Oligonucleotide-Enabled Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peptide and Oligonucleotide CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Contract Manufacturing Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Contract Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Biopharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION